Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01971684 · ClinicalTrials.gov registry record
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
A clinical trial, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- 120
- Enrollment target
NCT01971684 is a clinical trial that has completed, run by Boston Children's Hospital. The registered enrollment target is 120 participants.
The verdict
NCT01971684 has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to understand physician treatment decisions in selecting specific second line treatments in pediatric ITP and to determine the effectiveness of different second line ITP treatments. Eligible patients are those ages 1-18 years who are starting on a new second line treatment for ITP, defined as any treatment other than IVIG, steroids, anti-D globulin, or aminocaproic acid. Enrolled patients remain on the study for approximately one year.
Interventions
- DRUG Second Line ITP agents
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2013-08 |
| Est. Completion | 2017-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01971684
The ClinicalTrials.gov registry entry for NCT01971684 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Second Line ITP agents is the first listed.
NCT01971684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01971684 about?
NCT01971684 is a clinical study titled "ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP". The purpose of this study is to understand physician treatment decisions in selecting specific second line treatments in pediatric ITP and to determine the effectiveness of different second line ITP treatments. Eligible patients are those ages 1-18 years who are starting on a new second line treatme...
What is the current status of trial NCT01971684?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2013-08. Estimated completion is 2017-04.
What interventions are being tested in trial NCT01971684?
The interventions under investigation include: Second Line ITP agents (DRUG).
Who is sponsoring clinical trial NCT01971684?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.